Cargando…

Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand

BACKGROUND: The ataxia telangiectasia and Rad3-related (ATR) checkpoint kinase 1 (CHK1) pathway plays an essential role in suppressing replication stress from DNA damage and oncogene activation. MAIN BODY: Preclinical studies have shown that cancer cells with defective DNA repair mechanisms or cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mei, Lin, Zhang, Junran, He, Kai, Zhang, Jingsong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482552/ https://www.ncbi.nlm.nih.gov/pubmed/31018854 http://dx.doi.org/10.1186/s13045-019-0733-6

Ejemplares similares

Selective Elimination of Osteosarcoma Cell Lines with Short Telomeres by Ataxia Telangiectasia and Rad3-Related Inhibitors
por: Goncalves, Tomas, et al.
Publicado: (2020)

Quantitative Phosphoproteomics of the Ataxia Telangiectasia-Mutated (ATM) and Ataxia Telangiectasia-Mutated and Rad3-related (ATR) Dependent DNA Damage Response in Arabidopsis thaliana
por: Roitinger, Elisabeth, et al.
Publicado: (2015)

Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers
por: Savva, Constantinos, et al.
Publicado: (2019)

A function for ataxia telangiectasia and Rad3-related (ATR) kinase in cytokinetic abscission
por: Luessing, Janna, et al.
Publicado: (2022)

Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells
por: Jette, Nicholas R., et al.
Publicado: (2019)

Correction: Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells
por: Jette, Nicholas R., et al.
Publicado: (2020)

Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy
por: Al-Subhi, Nouf, et al.
Publicado: (2018)

The Role of Ataxia Telangiectasia Mutant and Rad3-Related DNA Damage Response in Pathogenesis of Human Papillomavirus
por: Luo, Ying, et al.
Publicado: (2020)

Experimental Antioxidant Therapy in Ataxia Telangiectasia
por: Reliene, Ramune, et al.
Publicado: (2008)

Sympathetic Modulation in Cardiac Arrhythmias: Where We Stand and Where We Go
por: Chung, Wei-Hsin, et al.
Publicado: (2023)

Myoclonus in Ataxia–Telangiectasia
por: Termsarasab, Pichet, et al.
Publicado: (2015)

Growth in ataxia telangiectasia
por: Natale, Valerie A. I., et al.
Publicado: (2021)

Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer
por: Shao, Jialu, et al.
Publicado: (2023)

mTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand?
por: Kezic, Aleksandra, et al.
Publicado: (2018)

Where Do We Stand?
Publicado: (1891)

Cancer: Where We Stand
Publicado: (1951)

Ataxia telangiectasia: Family management
por: Seshachalam, Arun, et al.
Publicado: (2010)

Ataxia-telangiectasia: future prospects
por: Chaudhary, Mohammed Wajid, et al.
Publicado: (2014)

Ataxia telangiectasia: a review
por: Rothblum-Oviatt, Cynthia, et al.
Publicado: (2016)

Correction to: Growth in ataxia telangiectasia
por: Natale, Valerie A. I., et al.
Publicado: (2021)

Gene therapy for arthritis – where do we stand?
por: Chernajovsky, Yuti
Publicado: (2005)

Topical therapy of psoriasis: Where do we stand?
por: Thappa, DM, et al.
Publicado: (2017)

Joint Discussion – Where we stand and where we want to go
por: CERN. Geneva
Publicado: (2013)

Joint Discussion – Where we stand and where we want to go
por: CERN. Geneva
Publicado: (2013)

Neutrino Masses and Mixing: Where We Stand and Where We are Going
por: Gonzalez-Garcia, M.C.
Publicado: (2002)

Alzheimer’s disease and infections, where we stand and where we go
por: Monastero, Roberto, et al.
Publicado: (2014)

Addictive behaviors: where do we stand, and where are we going?
por: Thibaut, Florence, et al.
Publicado: (2017)

Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR)
por: Wang, Li-Wei, et al.
Publicado: (2022)

Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells
por: Isono, Makoto, et al.
Publicado: (2022)

Stem Cell Therapy for Lower Extremity Diabetic Ulcers: Where Do We Stand?
por: Yang, Mei, et al.
Publicado: (2013)

Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells
por: Li, Lin, et al.
Publicado: (2023)

Hyperbaric oxygen therapy promotes neurogenesis: where do we stand?
por: Mu, Jun, et al.
Publicado: (2011)

A rad50 germline mutation induces tumorigenesis and ataxia-telangiectasia phenotype in a transparent medaka model
por: Chisada, Shinichi, et al.
Publicado: (2023)

Gravity: where do we stand ?
por: Peron, Roberto, et al.
Publicado: (2016)

Where we stand with the real superworld
por: Zichichi, Antonino
Publicado: (1993)

Correcting LEP: where we stand
por: Kleiss, R H
Publicado: (1989)

Recurrent Glioblastoma: Where we stand
por: Roy, Sanjoy, et al.
Publicado: (2015)

Corneal xenotransplantation: Where are we standing?
por: Yoon, Chang Ho, et al.
Publicado: (2021)

Immune checkpoint inhibitors in ovarian cancer: where do we stand?
por: Leary, Alexandra, et al.
Publicado: (2021)

Bladder Wall Telangiectasia in a Patient with Ataxia-Telangiectasia and How to Manage?
por: Aygün, Fatma Deniz, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_anogo02dri23ispb9dvps0er4q